mapping the effectiveness and risks of glp 1 GLP-1 receptor agonists GLP-1 Genetics: How Genes Affect
Description
Gabriele Faerber (Germany) Dr
GLP-1s are showing up at #CES2025 in many ways
DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect
But we think its diverse D2C offerings and strong subscriber growth should help insulate it financially.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and observational real-life studies
